Complement Activation Products and Cytokines in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
Angiogenesis Inhibitors
/ therapeutic use
Aqueous Humor
/ metabolism
Choroidal Neovascularization
/ drug therapy
Complement Activation
/ physiology
Cytokines
/ metabolism
Female
Humans
Intravitreal Injections
Male
Prospective Studies
Retinal Drusen
/ metabolism
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Wet Macular Degeneration
/ drug therapy
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
02 11 2020
02 11 2020
Historique:
entrez:
30
11
2020
pubmed:
1
12
2020
medline:
8
5
2021
Statut:
ppublish
Résumé
To investigate the characteristics of complement activation products and angiogenic cytokines in the aqueous humor in eyes with pachychoroid neovasculopathy (PNV) and neovascular age-related macular degeneration (nAMD). This was a prospective, comparative, observational study. All patients with choroidal neovascularization were classified as PNV without polyps, PNV with polyps (polypoidal choroidal vasculopathy [PCV]), or drusen-associated nAMD according to the presence or absence of pachychoroid features and soft drusen. This study included a total of 105 eyes. Aqueous humor samples were collected from 25 eyes with PNV without polyps, 23 eyes with PCV, and 24 eyes with drusen-associated nAMD before intravitreal anti-vascular endothelial growth factor (VEGF) injection and cataract surgery in 33 control eyes. Clinical samples were measured for complement component 3a (C3a), C4a, C5a, VEGF, and macrophage chemoattractant protein 1 (MCP-1) using a bead-based immunoassay. C3a and MCP-1 levels were significantly higher in PCV (P = 0.032 and P = 0.039, respectively) and drusen-associated nAMD (P = 0.01 for both comparisons) than in controls, and no difference was seen in C3a and MCP-1 levels between PNV and controls (P = 0.747 and P = 0.294, respectively). VEGF levels were significantly higher in PNV (P = 0.016), PCV (P = 0.009), and drusen-associated nAMD (P = 0.043) than in controls. In PNV, the VEGF levels elevated without elevated C3a and MCP-1. PNV, PCV, and drusen-associated nAMD had significantly distinct profiles of complement activation products and cytokines in the aqueous humor.
Identifiants
pubmed: 33252634
pii: 2772004
doi: 10.1167/iovs.61.13.39
pmc: PMC7705396
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Cytokines
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Références
Ophthalmic Res. 2020;63(3):252-258
pubmed: 31645047
Retina. 2015 Jan;35(1):1-9
pubmed: 25158945
Ophthalmology. 2009 Dec;116(12):2393-9
pubmed: 19815292
Mol Vis. 2012;18:574-80
pubmed: 22419849
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):376-382
pubmed: 30682207
Biomed Res Int. 2016;2016:6958752
pubmed: 27747237
Immun Ageing. 2016 Feb 16;13:4
pubmed: 26884800
Science. 2005 Apr 15;308(5720):421-4
pubmed: 15761121
Jpn J Ophthalmol. 2020 Jul;64(4):323-337
pubmed: 32318919
Eye (Lond). 2019 Dec;33(12):1859-1864
pubmed: 31267090
PLoS One. 2016 Jan 22;11(1):e0147346
pubmed: 26799405
Prog Retin Eye Res. 2016 Jan;50:1-24
pubmed: 26307399
Science. 2005 Apr 15;308(5720):385-9
pubmed: 15761122
Clin Exp Ophthalmol. 2018 Aug;46(6):661-669
pubmed: 29360187
Sci Rep. 2019 Dec 19;9(1):19447
pubmed: 31857597
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):292-298
pubmed: 28114590
Arch Ophthalmol. 2005 Nov;123(11):1570-4
pubmed: 16286620
Retina. 2013 Oct;33(9):1809-14
pubmed: 23492946
Mol Immunol. 2009 Sep;46(14):2753-66
pubmed: 19477527
Sci Rep. 2018 Jun 26;8(1):9679
pubmed: 29946065
Trans Am Ophthalmol Soc. 1977;75:180-254
pubmed: 613523
Retina. 1990;10(1):1-8
pubmed: 1693009
Arch Ophthalmol. 2007 Jan;125(1):55-62
pubmed: 17210852
Sci Rep. 2018 Jul 12;8(1):10520
pubmed: 30002400
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2328-33
pubmed: 16452172
Mol Diagn Ther. 2006;10(5):303-10
pubmed: 17022693
Diabetologia. 1999 Jul;42(7):870-7
pubmed: 10440131
Eye (Lond). 2017 May;31(5):810-813
pubmed: 28128795
Arch Ophthalmol. 2010 Oct;128(10):1281-6
pubmed: 20937997
Br J Ophthalmol. 2018 Apr;102(4):448-454
pubmed: 28765149
Eye (Lond). 1997;11 ( Pt 4):515-22
pubmed: 9425418
Mol Vis. 2009 Sep 19;15:1906-14
pubmed: 19784389
Nat Genet. 2006 Apr;38(4):458-62
pubmed: 16518403
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5924-5931
pubmed: 30551200
BMC Ophthalmol. 2020 Jan 8;20(1):15
pubmed: 31914968
Sci Rep. 2017 Mar 27;7:45081
pubmed: 28345626
Ophthalmology. 2009 Feb;116(2):304-10
pubmed: 19187823
Ophthalmologica. 2019;241(2):81-89
pubmed: 30048978
Acta Ophthalmol. 2020 Jun;98(4):384-389
pubmed: 31680415
Exp Eye Res. 2020 Jun;195:108025
pubmed: 32224205
Ophthalmic Res. 2015;53(1):2-7
pubmed: 25472810